SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

Company Overview

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Key Stats

• Today's Range: $2.82 to $2.98
• 50-Day Range: $2.66 to $3.68
• 52-Week Range: $2.58 to $6.28
• Volume: 28,816 shs
• Average Volume: 61,523 shs
• Market Capitalization: $190.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.80
• Consensus Rating: Moderate Buy

SOPHiA GENETICS Stock Analysis - MarketRank™

SOPHiA GENETICS scored higher than 35% of companies evaluated by MarketBeat, and ranked 722nd out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

SOPHiA GENETICS has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SOPHiA GENETICS is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SOPHiA GENETICS is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 8.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SOPHiA GENETICS does not currently pay a dividend.

Dividend Growth

SOPHiA GENETICS does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 8.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.

Percentage Held by Institutions

Only 31.59% of the stock of SOPHiA GENETICS is held by institutions.

SOPH Stock Analysis - Frequently Asked Questions

How have SOPH shares performed this year?

SOPHiA GENETICS's stock was trading at $3.07 at the start of the year. Since then, SOPH shares have decreased by 7.2% and is now trading at $2.85.
View the best growth stocks for 2025 here.

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) posted its earnings results on Tuesday, May, 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. The firm earned $17.78 million during the quarter, compared to analysts' expectations of $16.76 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 55.06% and a negative net margin of 110.71%.
Read the conference call transcript.

When did SOPHiA GENETICS IPO?

SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

Who are SOPHiA GENETICS's major shareholders?

Top institutional investors of SOPHiA GENETICS include UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (11.45%), Banque Pictet & Cie SA (3.32%), Principal Financial Group Inc. (2.08%) and Bank Pictet & Cie Europe AG (0.38%).

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SOPHiA GENETICS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/25/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SOPH
• CIK: 1840706
• Web: www.sophiagenetics.com
• Phone: 41-21-694-1060
• Fax: N/A
• Employees: 520
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.80
• High Stock Price Target: $11.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +138.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-78,980,000.00
• Net Margins: -110.71%
• Pretax Margin: -109.76%
• Return on Equity: -55.06%
• Return on Assets: -38.33%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 3.80
• Quick Ratio: 3.59

Sales & Book Value

• Annual Sales: $67.17 million
• Price / Sales: 2.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 66,687,000
• Free Float: 62,185,000
• Market Cap: $190.06 million
• Optionable: Not Optionable
• Beta: 1.03